Cost-Effectiveness of Treatments for Diabetic Macular Edema: Simulated Bevacizumab-First Step Therapy Versus Real-World Practice.

To compare the incremental cost-effectiveness of a clinical trial-simulated step-therapy versus real-world treatment for diabetic macular edema (DME). A theoretical Markov model (follow-up of 2 years and lifetime of 17 years) from the 2025 US societal perspective was used to compare the costs and cost-effectiveness between bevacizumab-first (Protocol AC) and real-world regimens from the Vestrum Health database. The modeling used mean characteristics from a reference case and analyzed low- and high-cost scenarios, total societal costs from formal and informal healthcare and non-healthcare sectors, and differences in utility (visual acuity outcomes) between arms.

Supply Chain Volatility of Repackaged Intravitreal Bevacizumab: A Survey of the American Society of Retina Specialists.

To characterize retina specialists' perceptions of the intravitreal (IVT) bevacizumab supply chain after the manufacturer, Pine Pharmaceuticals, announced they would no longer produce the formulation. A 22-question survey was created to assess retina physicians' use of IVT bevacizumab, perceptions of the supply chain, and how the decision will affect patient care. The survey was electronically distributed to all members of the American Society of Retina Specialists.

Bevacizumab First in DRCR Protocol AC vs Real-World Physician Treatment Choice for Diabetic Macular Edema: Two-Year Cost Analysis.

To compare the modeled costs of the Protocol AC bevacizumab-first treatment protocol (with a switch to aflibercept for sub-responders) with real-world costs for treatment-naïve patients with diabetic macular edema (DME) over a 2-year period. Published data from the Diabetic Retinopathy Clinical Research Network (DRCR) Protocol AC bevacizumab-first arm (154 eyes) were used to model 2-year treatment costs. Real-world costs were modeled using data from the Vestrum Health electronic medical records database from a 2016 to 2018 cohort of treatment-naïve eyes with DME (n = 1062) treated with antivascular endothelial growth factor monotherapy.

"We don't really address the trauma": Patients' Perspectives on Postpartum Care Needs after Severe Maternal Morbidities.

Objectives: This qualitative study explored experiences of 15 women in New York City who suffered physical, emotional, and socioeconomic consequences of severe maternal morbidity (SMM). This study aimed to increase our understanding of additional burdens these mothers faced during the postpartum period.

Methods: Qualitative analysis of in-depth interviews (n = 15) with women who had given birth in NYC hospitals and experienced SMM.

Perinatal Mood and Anxiety Disorder and Reproductive Justice: Examining Unmet Needs for Mental Health and Social Services in a National Cohort.

Introduction: Perinatal Mood and Anxiety Disorders (PMADs) are the most common complications during the perinatal period. There is limited understanding of the gaps between need and provision of comprehensive health services for childbearing people, especially among racialized populations.

Methods: The Giving Voice to Mothers Study (GVtM; =2700), led by a multistakeholder, Steering Council, captured experiences of engaging with perinatal services, including access, respectful care, and health systems' responsiveness across the United States.